1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. RUBICON RESEARCH LTD.
Rubicon Research Ltd.
NSE: RUBICON | BSE: 544578|ASM

Rubicon Research Live Share Price Today, Share Analysis and Chart

Expensive Star
aboutRubicon Research Ltd. is a pharmaceutical company that has transitioned from a contract research provider to a specialty products firm. It focuses on developing, manufacturing, and commercializing high-value, complex generic and specialty formulation... Read More
Ask AI about Rubicon Research
1610.5051.20(3.28%)

165.26% Gain from 52W Low

217.4K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Rubicon Research is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
64.0 / 100
Expensive StarThese stocks are bullish, strong in quality and technicals, but expensive in valuation. Investors need to be cautiousView SimilarEmbed DVM
Analyst Price Target
No estimates available

30

S

7

W

7

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive7Negative

Pass in checklist68.2%

045
55
100

Check P/E Buy Sell Zone

Sell Zone

75.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Rubicon Research Stock Price Analysis

Day Price Range

3.3% 1 Day return
1610.5 (LTP)
1,537.91,628.8
LowHigh

Week Price Range

13.1% 1 Week return
1610.5 (LTP)
1,424.41,628.8
LowHigh

Month Price Range

0.1% 1 Month return
1610.5 (LTP)
1,390.51,670
LowHigh

52 Week Price Range

164.1% 1 Year return
1610.5 (LTP)
607.21,899
LowHigh
View full Price History/Seasonality

Rubicon Research Technical Analysis

Rubicon Research EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1553.9
10 Day1532.8
12 Day1532.6
20 Day1548.0
26 Day1562.6
50 Day1582.0
100 Day1497.2
200 Day1233.0

Rubicon Research Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202652.6%
Week44.0%
Month54.6%

Rubicon Research Active Candlesticks

Engulfing Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Rubicon Research Resistance and Support

1592.40
Pivot
First Resistance1646.9
Second Resistance1683.3
Third Resistance1737.8
First Support1556
Second Support1501.5
Third Support1465.1
Day RSI56.2
Day MACD-30
Day MFI40
Day MACD Signal Line-47.6

Rubicon Research Beta

1 Month0.3
1 Year0.4
3 Month-0.1
3 Year-

Rubicon Research Price Change Analysis

↑0.1%
Over 1 Month
LowHigh
1390.51670
↑7.4%
Over 3 Months
LowHigh
1390.51899
↑65.1%
Over 6 Months
LowHigh
9181899
↑164.1%
Over 1 Year
LowHigh
607.21899
All Technicals →

Rubicon Research Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
General Atlantic Singapore Rr Pte LtdPromoter45,258,36027.3 %
Fidelity Funds - India Focus FundFii2,039,7721.2 %
HufPublic22,548,77013.6 %
Kotak Midcap FundDii6,769,4424.1 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Rubicon Research Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 20261660843,372NSE
ARANDA INVESTMENTS PTE. LTD.BlockPurchase26 Aug 20261660843,372NSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBulkSell26 Aug 20261660843,372NSE
ARANDA INVESTMENTS PTE. LTD.BulkPurchase26 Aug 20261660843,372NSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 202616604,878,009BSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 202616601,807,226BSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 202616601,656,624BSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 202616601,204,815BSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 202616601,203,999BSE
GENERAL ATLANTIC SINGAPORE RR PTE LTDBlockSell26 Aug 20261660903,611BSE
All deals
All insider trades

Rubicon Research Corporate Actions

Rubicon Research Dividend history and yield

Rubicon Research dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Rubicon Research dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
107 Aug 2026
1.5FINAL07 Aug 2026Equity Share

Rubicon Research Board Meetings

Rubicon Research past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
214 Aug 2026
Quarterly Results-
329 May 2026
Audited Results & Final Dividend-
403 Feb 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-
All Corporate Actions

Rubicon Research Research Reports

Rubicon Research research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
114 Aug 2026Motilal Oswal
Target
19151619.1Buy18.28%-0.53%pdf
229 May 2026Motilal Oswal
Target
11601005.6Buy15.35%60.15%pdf
314 Apr 2026Motilal Oswal
Target
955821.3Buy16.28%96.09%pdf
412 Nov 2025Motilal Oswal
Target
780654.35Buy19.2%146.12%pdf
530 Oct 2025Motilal Oswal740609.8Buy21.35%164.1%pdf
All Reports of Rubicon

Rubicon Research Corporate Filings

Rubicon Research BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Rubicon Research Ltd - 544578 - Outcome Of USFDA Inspection Of Rubicon Research Ltd, Manufacturing Facility In Ambernath, India.
Outcome of USFDA Inspection of Rubicon Research Ltd Manufactiring Facility at Ambernath, India
PDF
28 Oct 2026
Rubicon Research Ltd - 544578 - Intimation Regarding Q2 Earnings Conference Call.
Intimaiton regarding Q2 Earnings Conference Call.
PDF
27 Oct 2026
Rubicon Research Ltd - 544578 - Board Meeting Intimation for Q 2 Ended September, 2026.
Rubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve The Un-Audited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2026
PDF
09 Oct 2026
Rubicon Research Ltd - 544578 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -US FDA Inspection Of The Company''s Manufacturing Facility In Satara, Maharashtra, India.
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of the Company''s manufacturing facility in Satara, Maharashtra, India
PDF
09 Oct 2026
Rubicon Research Ltd - 544578 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
PDF
VIEW ALL

Rubicon Research DocumentsAsk MarketMind AI

Rubicon Research Earnings Call

Rubicon Research earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
19 Aug 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
14 Aug 2026Rubicon Research Ltd - 544578 - Audio Recording Of Earnings Conference Call For The Quarter Ended 30Th June, 2026.Link
02 Jun 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
30 May 2026Rubicon Research Ltd - 544578 - Earnings Call Audio RecordingLink
06 Feb 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Rubicon Research Annual Reports

Rubicon Research financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link

Rubicon Research Credit Ratings

Rubicon Research credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
14 Oct 2026india ratingsIndia Ratings Upgrades Rubicon Research’s Bank Loans Facilities to ‘IND A’; Outlook Positive; Rates Additional LimitsLink

Rubicon Research Investor Presentations

Rubicon Research investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
14 Aug 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
29 May 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
03 Feb 2026Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
13 Nov 2025Rubicon Research Ltd - 544578 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Rubicon Research - Company Profile

Rubicon Research Management Structure

Rubicon Research management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
PARAG SUGANCHAND SANCHETIExecutive Director,Chief Executive Officer560Mar 26
Mr. Sudhir Dhirendra PilgaonkarSenior Vice President-Mar 26
Mrs. Surabhi Parag SanchetiExecutive Vice President(Business Development,Project Management)-Mar 26
Mr. Sumant Sudhir PilgaonkarSenior Vice President - Operations(Operations)-Mar 26
Mr. Nitin JajodiaChief Financial Officer-Mar 26
Mr. Sarabjit SinghExecutive Vice President(Research & Development)-Mar 26
Ms. Romola PintoVice President(Human Resources,Administration)-Mar 26
Mr. Sanjay Dinkar RenapurkarVice President(Corporate Quality Assurance)-Mar 26
Mr. Sagar Pradeep OakSenior Vice President(Corporate Development,Strategy)-Mar 26
Ms. Daliya BharatiDirector(Regulatory Affairs,Intellectual Property)-Mar 26
Mr. Louis E.L. CoutinhoHead(Global Quality)-Mar 26
Mr. Narendra BorkarPresident,Director (Operations)-Mar 26
Ms. Avani ShahGeneral Manager(Legal and Secretarial,Compliance)-Mar 26
DEEPASHREE OMKAR TANKSALECompany Secretary,Compliance Officer-Mar 26

Rubicon Research Board of Directors

Rubicon Research Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Parag Suganchand SanchetiExecutive Director & CEO560Mar 26
Pratibha PilgaonkarED / MD / Promoter176Mar 26
Milind PatilIndependent Non Exe. Director30Mar 26
K G AnanthakrishnanIndependent Non Exe. Director25Mar 26
Venkat ChangavalliChairman & Independent Directo25Mar 26
Pradnya SaravadeIndependent Non Exe. Director4Mar 26
Deepashree TanksaleCompany Sec. & Compli. Officer-Mar 26
Varun TalukdarNon-Exec & Non-Independent Dir-Mar 26
Shantanu RastogiNon-Exec & Non-Independent Dir-Mar 26
Website: www.rubicon.co.in

About the company - Business Profile

Rubicon Research Ltd. is a pharmaceutical company that has transitioned from a contract research provider to a specialty products firm. It focuses on developing, manufacturing, and commercializing high-value, complex generic and specialty formulations. The company operates across the drug lifecycle, from initial research and development to commercial manufacturing and front-end marketing, primarily targeting the regulated U.S. market.

Key Points

  • Key Facts: Founded in 1999 and headquartered in Mumbai, India, Rubicon Research Ltd. successfully listed on the Indian stock exchanges following its IPO in October 2025.
  • Operations and Resources: The company operates three manufacturing sites and two USFDA-inspected R&D facilities located in India (Ambernath, Satara, and Pithampur) and Canada. Its Thane R&D facility spans approximately 38,000 sq. ft. and includes specialized laboratories for general, sterile, and potent compounds.
  • Ownership and Privatization: Originally a family-owned entity, it received private equity backing and reached its current scale through a combination of internal accruals and strategic capital raises. Following its IPO in October 2025, the company is now a public entity with net IPO proceeds of approximately ₹478 crore.
  • Market and Significance: The company has a significant presence in the U.S., where it achieves a 92.68% commercialization rate (76 out of 82 approved products). It serves the non-branded prescription market via its subsidiary Advagen and the branded specialty market via Validus Pharmaceuticals.
  • Business Model and Core Strengths: Rubicon follows a vertically integrated model focusing on specialized dosage forms like oral solids, liquids, ointments, and nasal sprays. Its core strength lies in its high R&D intensity, with R&D expenses consistently making up 10% to 11% of operating revenue.

Financial and Operational Performance

  • Revenue Breakdown:
    • FY2025 Revenue: ₹1,284.3 crore (Operating Revenue)
    • 9M FY2026 Revenue: ₹1,240 crore (33.9% growth year-on-year)
    • Geographical Concentration: The primary revenue driver is the U.S. market, facilitated by its wholly-owned subsidiaries.
  • Key Financial Ratios (FY2025):
    • EBITDA Margin: 21%
    • PAT Margin: 11%
    • ROACE (Pre-tax): 30% (increased to 34% in 9M FY2026)
  • Products and Technology:
    • Branded Portfolio: Markets unique brands like Raldesy, LopressorOS, and Equetro, which currently have no USFDA-approved substitutable generics.
    • Pipeline and Approvals: As of September 30, 2025, the company had 82 active approved products.
  • Human Resources: The company employs over 600 professionals, including a team of 190+ dedicated R&D scientists as of late 2025.
  • Strategic Initiatives:
    • Acquisitions: Recently acquired a manufacturing site in Pithampur for ₹149 crore and invested in Gen1 Life Sciences.
    • Portfolio Diversification: Successfully reduced product concentration; the Top 5 products accounted for 31% of revenue in H1 FY2026, down from 51% in FY2023.
    • Future Outlook: Strategic expansion into drug-device combinations (nasal sprays) and branded specialty products.

References

  1. Investor Presentation Feb 2026
  2. Investor Presentation Nov 2025

Rubicon Research FAQ

Rubicon Research today is trading in the green, up by 3.28% at ₹1,610.5.
Rubicon Research is currently trading up 3.28% on an intraday basis. In the past week the stock rose 13.07%. Stock has been up 7.35% in the past quarter and rose 164.1% in the past year. You can view this in the share price history/seasonality section.
Rubicon Research is listed on NSE with the ticker RUBICON and on BSE as 544578. It's currently trading on NSE at a share price of ₹1,610.5 and on BSE with a share price of ₹1,609.9.
The market cap of Rubicon Research is ₹26,658.91 Cr. as of Oct 30, 2026.
Rubicon Research announced a FINAL dividend of 150% which equals ₹1.5 in Aug 07, 2026.To view the full dividend history of Rubicon Research click here.
Rubicon Research has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Rubicon Research reported ₹540.02 Cr. in revenue, ₹84.78 Cr. in net profit, and ₹134.8 Cr. in EBITD as of Aug 14, 2026 for Q1 FY26-27.
There are no analyst predictions for stock price target for Rubicon Research.
The PE ratio of Rubicon Research is 92.5 as of Oct 30, 2026.
The PB ratio of Rubicon Research is 19.41 as of Oct 30, 2026.
You can view the latest analyst reports on the Rubicon Research reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×